OncoMatch/Clinical Trials/NCT05272293
Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML
Is NCT05272293 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies NK cell infusions for acute myeloid leukemia.
Treatment: NK cell infusions — The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells for children/young adults with primary high risk or refractory AML and relapsed AML.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Demographics
Lab requirements
Liver function
SGOT or SCPT >=5x upper limit of normal for age [excluded]
severe hepatic dysfunction: SGOT or SCPT >=5x upper limit of normal for age
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05272293 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 30 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages